{"ResultsReport": {"xmlns": "http://integration.foundationmedicine.com/reporting", "xmlnsxsi": "http://www.w3.org/2001/XMLSchema_instance", "xsischemaLocation": "http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd", "CustomerInformation": {"ReferenceID": "01_2022_00024765", "CSN": null, "TRF": "ORD_1504083_01", "MRN": "30426223", "PhysicianId": "109266", "NPI": "International"}, "ResultsPayload": {"FinalReport": {"xmlnsxsd": "http://www.w3.org/2001/XMLSchema", "StagingId": "1225040", "clinicalId": "1226410", "xsinoNamespaceSchemaLocation": "http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd", "Application": {"ApplicationSettings": {"ApplicationSetting": {"Name": "Statement", "Value": null}}}, "DemographicCorrectionDate": null, "ReportId": "ORD_1504083_01", "SampleName": "US1439344.01", "Version": "0", "Sample": {"FM_Id": "ORD_1504083_01", "SampleId": "US1439344.01", "BlockId": "nan", "TRFNumber": "ORD_1504083_01", "TestType": "FoundationOne Liquid  ", "SpecFormat": "Blood", "ReceivedDate": "2022_11_14", "processSites": {"processSite": [{"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "Extracted DNA"}, {"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "LC"}]}, "TumorPurity": "ETFND", "SpecimenLocation": "nan"}, "PMI": {"ReportId": "M111-10015", "MRN": "30426223", "FullName": "\u9673\u7cd6", "FirstName": "Tang", "LastName": "Chen", "SubmittedDiagnosis": "Adenocarcinoma, Cervix", "Gender": "Female", "DOB": "1957_09_15", "OrderingMD": "\u6d2a\u7165\u7a0b", "OrderingMDId": "109266", "Pathologist": "\u9673\u5fd7\u5b78", "CopiedPhysician1": null, "MedFacilName": "Taipei Veterans General Hospital", "MedFacilID": "205872", "SpecSite": "Blood", "CollDate": "2022_11_09", "ReceivedDate": "2022-11-25 00:00:00", "CountryOfOrigin": "TW", "TumorType": "Cervical Cancer"}, "PertinentNegatives": null, "Summaries": {"alterationCount": "7", "clinicalTrialCount": "0", "resistiveCount": "0", "sensitizingCount": "0"}, "VariantProperties": {"VariantProperty": [{"geneName": "APC", "isVUS": "true", "variantName": "A2778S"}, {"geneName": "ERBB2", "isVUS": "true", "variantName": "A466V"}, {"geneName": "NOTCH3", "isVUS": "true", "variantName": "R544C"}, {"geneName": "TNFAIP3", "isVUS": "true", "variantName": "P714S"}]}, "priorTests": null, "Genes": {"Gene": [{"Name": "Blood Tumor Mutational Burden", "Include": "true", "Alterations": {"Alteration": {"Name": "00", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "00"}}, "Interpretation": "Blood tumor mutational burden (bTMB, also known as mutation load) is a measure of the number of somatic protein_coding base substitution and insertion/deletion mutations from circulating tumor DNA in blood. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide_based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). High bTMB levels were not detected in this sample. It is unclear whether the bTMB levels in this sample would be predicted to be associated with sensitivity to PD_1_ or PD_L1_targeting immune checkpoint inhibitors, alone or in combination with other agents (Socinski et al., 2019 ESMO Abstract LBA83, Gandara et al., 2018; 30082870, Wang et al., 2019; 30816954, Aggarwal et al., 2020; 32102950, Rizvi et al., 2019; ASCO Abstract 9016). Depending on the clinical context, TMB testing of an alternate sample or by another methodology could be considered. Average bTMB levels in solid tumors other than NSCLC have not been evaluated (PubMed, Mar 2022). One study reported that cervical carcinoma harbors a median tumor mutational burden (mTMB) of 4.4 Muts/Mb and a TMB \u226510 Muts/Mb in 15_21% of cases (Shao et al., 2020; 33119110, Huang et al., 2021; SGO Abstract 371). For cervical squamous cell carcinoma and cervical adenocarcinoma, studies reported an mTMB of 3.7_5.4 and 1.6_3.6 Muts/Mb, respectively, and a high TMB (>20 Muts/Mb) in 6.7% and 3.6% of cases, respectively (FMI_Chalmers et al., 2017; 28420421, Ojesina et al., 2014; 24390348). For patients with advanced cervical carcinoma not treated with immunotherapy, OS did not significantly differ between patients with TMB_high (\u226510 mut/Mb) and TMB_low (<10 Muts/Mb), although relatively few patients had TMB_high cervical carcinoma in this analysis (n=17) (Shao et al., 2020; 33119110). On the basis of clinical evidence in solid tumors, increased blood tumor mutational burden (bTMB) may be associated with greater sensitivity to immunotherapeutic agents, including anti_PD_L1 (Socinski et al., 2019 ESMO Abstract LBA83, Gandara et al., 2018; 30082870, Wang et al., 2019; 30816954, Li et al., 2020; ASCO Abstract 6511, Saori et al., 2021; ESMO Abstract 80P, Sturgill et al., 2022; 35274716), anti_PD_1 (Schenker et al., 2022; AACR Abstract CT022, Aggarwal et al., 2020; 32102950, Peters et al., 2019; AACR Abstract CT074, Saori et al., 2021; ESMO Abstract 80P, Sturgill et al., 2022; 35274716), anti_PD_1/CTLA4 therapies (Schenker et al., 2022; AACR Abstract CT022, Saori et al., 2021; ESMO Abstract 80P), anti_PD_L1/CTLA4 therapies (Chen et al., 2020; 32379280, Loree et al., 2021; ASCO GI Abstract 61, Li et al., 2020; ASCO Abstract 6511, Rizvi et al., 2020; 32271377, Si et al., 2021; 33355200, Leighl et al., 2022; 34800700). A Phase 2 multi_solid_tumor trial showed that bTMB \u226516 Muts/Mb (as measured by this assay) was associated with improved survival from treatment with a PD_1 inhibitor alone or in combination with a CTLA_4 inhibitor (Schenker et al., 2022; AACR Abstract CT022). In non_small cell lung cancer (NSCLC), multiple clinical trials have shown patients with higher bTMB derive clinical benefit from immune checkpoint inhibitors following single_agent or combination treatments with either CTLA4 inhibitors or chemotherapy, with reported high bTMB cutpoints ranging from 6 Muts/Mb_16 Muts/Mb (Gandara et al., 2018; 30082870, Socinski et al., 2019 ESMO Abstract LBA83, Aggarwal et al. 2020; 32102950, Rizvi et al., 2020; 32271377, Si et al., 2021; 33355200, Leighl et al., 2022; 34800700). In head and neck squamous cell carcinoma (HNSCC), a Phase 3 trial showed that bTMB \u226516 Muts/Mb (approximate equivalency \u22658 Muts/Mb as measured by this assay) was associated with improved survival from treatment with a PD_L1 inhibitor alone or in combination with a CTLA_4 inhibitor (Li et al., 2020; ASCO Abstract 6511). In colorectal cancer (CRC), a Phase 2 study showed that bTMB TMB \u226528 Muts/Mb (approximate equivalency \u226514 Muts/Mb as measured by this assay) was associated with improved OS from a PD_L1 inhibitor alone or in combination with a CTLA_4 inhibitor (Loree et al., 2021; ASCO GI Abstract 61, Chen et al., 2020; 32379280).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Microsatellite status", "Include": "true", "Alterations": {"Alteration": {"Name": "Cannot Be Determined", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "Cannot Be Determined"}}, "Interpretation": "Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). The level of MSI in this sample could not be determined with confidence. Depending on the clinical context, MSI testing of an alternate sample or by another methodology could be considered. MSI has been reported at a lower frequency in cervical cancer than in endometrial cancer (Helland et al., 1997; 9052745). A non_zero level of MSI has been reported in 5_25% (n = 38_100) of cervical carcinoma cases (Rodriguez et al., 1998; 9990486, Ercoli et al., 2005; 15823117, Helland et al., 1997; 9052745, Baay et al., 2009; 19480245, Chung et al., 2001; 11134837, Nishimura et al., 2000; 11063644), and was not associated with HPV infection status (Rodriguez et al., 1998; 9990486, Nishimura et al., 2000; 11063644). In cervical squamous cell carcinoma (SCC) specifically, MSI_L and MSI_H have been reported in 12_17% and MSI_H in 12_14% of samples, respectively (n = 50_93) (Chung et al., 2001; 11586036, Wong et al., 2003; 12798708), including in 18% (9/50) and 2% (1/50) of early stage cases (Clarke et al., 2003; 14615820). In cervical adenocarcinoma, MSI_L has been detected in 16% (6/37) and MSI_H in 11% (4/37) of cases (Miyai et al., 2004; 15262128). MSI positivity has been reported to be significantly more frequent in invasive cervical carcinoma over cervical carcinoma in situ (Nishimura et al., 2000; 11063644) and in cervical SCC over cervical intraepithelial neoplasia (Wong et al., 2003; 12798708). Although a few studies have reported MSI positivity in cervical SCC to correlate with advanced stage (Chung et al., 2001; 11586036) or poorer overall survival (Wong et al., 2003; 12798708), several others have reported no association between MSI status and clinicopathologic features and/or prognosis in cervical carcinoma, including SCC (Wong et al., 2003; 12798708, Baay et al., 2009; 19480245, Clarke et al., 2003; 14615820, Helland et al., 1997; 9052745, Chung et al., 2001; 11134837, Nishimura et al., 2000; 11063644). On the basis of prospective clinical evidence in multiple solid tumor types, microsatellite instability (MSI) and associated increased tumor mutational burden (TMB) (Jass, 2007; 17204026, Lal et al., 2015; 25949894) may predict sensitivity to immune checkpoint inhibitors, including the approved PD_1_targeting agents cemiplimab, dostarlimab, nivolumab (alone or in combination with ipilimumab), and pembrolizumab (Overman et al., 2017; 28734759, Overman et al., 2018; 29355075, Overman et al., 2019; ASCO Abstract 635, Shitara et al., 2022; 35322232, Andre et al., 2022; ASCO GI Abstract 244, Lipson et al., 2013; 23169436, Le et al., 2015; 26028255, Rizvi et al., 2015; 25765070, Oaknin et al., 2020; 33001143), as well as PD_L1_targeting agents atezolizumab, avelumab, and durvalumab (Hochster et al., 2017; ASCO Abstract 673, Fleming et al., 2018; ASCO Abstract 5585, Bang et al., 2018; ASCO Abstract 92). As the MSI status of this tumor is unknown, the relevance of these therapeutic approaches is unclear.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Tumor Fraction", "Include": "true", "Alterations": {"Alteration": {"Name": "Elevated Tumor Fraction Not Detected", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "Elevated Tumor Fraction Not Detected"}}, "Interpretation": "Tumor fraction provides an estimate of the percentage of ctDNA present in a cell_free DNA (cfDNA) sample. The tumor fraction estimate for this sample is based on the observed level of aneuploid instability. The tumor fraction algorithm utilized for FoundationOne Liquid CDx uses the allele frequencies of approximately 1,000 single_nucleotide polymorphism (SNP) sites across the genome. Unlike the maximum somatic allele frequency (MSAF) method of estimating ctDNA content (Li et al., 2019; 31602320), the tumor fraction metric does not take into account the allele frequency of individual variants but rather produces a more holistic estimate of ctDNA content using data from across the genome. The amount of ctDNA detected may correlate with disease burden and response to therapy (Zhang et al., 2020; 32757294, Butler et al., 2019; 30833418). Detectible ctDNA levels have been reported in a variety of tumor types, with higher tumor fraction levels reported for patients with metastatic (Stage 4) tumors compared with patients with localized disease (Stages 1 to 3) (Bettegowda et al., 2014; 24553385). Elevated tumor fraction levels have been reported to be associated with worse prognosis in a variety of cancer types, including pancreatic cancer (Lapin et al., 2018; 30400802), Ewing sarcoma and osteosarcoma (Shulman et al., 2018; 30131550), prostate cancer (Choudhury et al., 2018; 30385733, Conteduca et al., 2019; ASCO abstract 5039), breast cancer (Stover et al., 2018; 29298117), leiomyosarcoma (Hemming et al., 2019; 30793095), esophageal cancer (Egyud et al., 2019; 31059681), colorectal cancer (Fan et al., 2017; 28187169), and gastrointestinal cancer (Vu et al., 2020; DOI: 10.1200/PO.19.00204). Specimens with elevated tumor fraction values have high circulating_tumor DNA (ctDNA) content, and thus high sensitivity for identifying genomic alterations. Such specimens are at low risk of false negative results. However, if elevated tumor fraction is not detected, it does not exclude the presence of disease burden or compromise the confidence of reported alterations. Tumor fraction levels currently have limited implications for diagnosis, surveillance, or therapy and should not be overinterpreted or compared from one blood draw to another. There are currently no targeted approaches to address specific tumor fraction levels. In the research setting, changes in tumor fraction estimates have been associated with treatment duration and clinical response and may be a useful indicator for future cancer management (Bronkhorst et al., 2019; 30923679, Raja et al., 2018; 30093454, Hrebien et al., 2019; 30860573, Conteduca et al., 2019; ASCO Abstract 5039, Choudhury et al., 2018; 30385733, Goodall et al., 2017; 28450425, Goldberg et al., 2018; 29330207).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}]}, "Trials": null, "References": {"Reference": [{"number": "0", "ReferenceId": "15748635", "FullCitation": "Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635", "Include": "true"}, {"number": "1", "ReferenceId": "23875803", "FullCitation": "Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803", "Include": "true"}, {"number": "2", "ReferenceId": "12379884", "FullCitation": "Pfeifer GP, et al. Oncogene (2002) pmid: 12379884", "Include": "true"}, {"number": "3", "ReferenceId": "25765070", "FullCitation": "Rizvi NA, et al. Science (2015) pmid: 25765070", "Include": "true"}, {"number": "4", "ReferenceId": "24336570", "FullCitation": "Johnson BE, et al. Science (2014) pmid: 24336570", "Include": "true"}, {"number": "5", "ReferenceId": "29452419", "FullCitation": "Choi S, et al. Neuro_oncology (2018) pmid: 29452419", "Include": "true"}, {"number": "6", "ReferenceId": "23636398", "FullCitation": "Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398", "Include": "true"}, {"number": "7", "ReferenceId": "23447401", "FullCitation": "Briggs S, et al. J. Pathol. (2013) pmid: 23447401", "Include": "true"}, {"number": "8", "ReferenceId": "24583393", "FullCitation": "Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393", "Include": "true"}, {"number": "9", "ReferenceId": "22810696", "FullCitation": "Nature (2012) pmid: 22810696", "Include": "true"}, {"number": "10", "ReferenceId": "25568919", "FullCitation": "Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919", "Include": "true"}, {"number": "11", "ReferenceId": "30082870", "FullCitation": "Gandara DR, et al. Nat. Med. (2018) pmid: 30082870", "Include": "true"}, {"number": "12", "ReferenceId": "30816954", "FullCitation": "Wang Z, et al. JAMA Oncol (2019) pmid: 30816954", "Include": "true"}, {"number": "13", "ReferenceId": "32102950", "FullCitation": "Aggarwal C, et al. Clin. Cancer Res. (2020) pmid: 32102950", "Include": "true"}, {"number": "14", "ReferenceId": "33119110", "FullCitation": "Shao C, et al. JAMA Netw Open (2020) pmid: 33119110", "Include": "true"}, {"number": "15", "ReferenceId": "28420421", "FullCitation": "Chalmers ZR, et al. Genome Med (2017) pmid: 28420421", "Include": "true"}, {"number": "16", "ReferenceId": "24390348", "FullCitation": "Ojesina AI, et al. Nature (2014) pmid: 24390348", "Include": "true"}, {"number": "17", "ReferenceId": "35274716", "FullCitation": "Sturgill EG, et al. Oncologist (2022) pmid: 35274716", "Include": "true"}, {"number": "18", "ReferenceId": "32379280", "FullCitation": "Chen EX, et al. JAMA Oncol (2020) pmid: 32379280", "Include": "true"}, {"number": "19", "ReferenceId": "32271377", "FullCitation": "Rizvi NA, et al. JAMA Oncol (2020) pmid: 32271377", "Include": "true"}, {"number": "20", "ReferenceId": "33355200", "FullCitation": "Si H, et al. Clin Cancer Res (2021) pmid: 33355200", "Include": "true"}, {"number": "21", "ReferenceId": "34800700", "FullCitation": "Leighl NB, et al. J Thorac Oncol (2022) pmid: 34800700", "Include": "true"}, {"number": "22", "ReferenceId": "26337942", "FullCitation": "Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942", "Include": "true"}, {"number": "23", "ReferenceId": "21081928", "FullCitation": "You JF, et al. Br. J. Cancer (2010) pmid: 21081928", "Include": "true"}, {"number": "24", "ReferenceId": "24623249", "FullCitation": "Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249", "Include": "true"}, {"number": "25", "ReferenceId": "9052745", "FullCitation": "Helland A, et al. Int. J. Cancer (1997) pmid: 9052745", "Include": "true"}, {"number": "26", "ReferenceId": "9990486", "FullCitation": "Rodriguez JA, et al. Diagn. Mol. Pathol. (1998) pmid: 9990486", "Include": "true"}, {"number": "27", "ReferenceId": "15823117", "FullCitation": "Ercoli A, et al. Int. J. Gynecol. Cancer () pmid: 15823117", "Include": "true"}, {"number": "28", "ReferenceId": "19480245", "FullCitation": "Baay MF, et al. Eur. J. Gynaecol. Oncol. (2009) pmid: 19480245", "Include": "true"}, {"number": "29", "ReferenceId": "11134837", "FullCitation": "Chung TK, et al. Eur. J. Obstet. Gynecol. Reprod. Biol. (2001) pmid: 11134837", "Include": "true"}, {"number": "30", "ReferenceId": "11063644", "FullCitation": "Nishimura M, et al. Gynecol. Oncol. (2000) pmid: 11063644", "Include": "true"}, {"number": "31", "ReferenceId": "11586036", "FullCitation": "Chung TK, et al. Gynecol. Obstet. Invest. (2001) pmid: 11586036", "Include": "true"}, {"number": "32", "ReferenceId": "12798708", "FullCitation": "Wong YF, et al. Gynecol. Oncol. (2003) pmid: 12798708", "Include": "true"}, {"number": "33", "ReferenceId": "14615820", "FullCitation": "Clarke B, et al. Int. J. Surg. Pathol. (2003) pmid: 14615820", "Include": "true"}, {"number": "34", "ReferenceId": "15262128", "FullCitation": "Miyai K, et al. Gynecol. Oncol. (2004) pmid: 15262128", "Include": "true"}, {"number": "35", "ReferenceId": "17204026", "FullCitation": "Histopathology (2007) pmid: 17204026", "Include": "true"}, {"number": "36", "ReferenceId": "25949894", "FullCitation": "Lal N, et al. Oncoimmunology (2015) pmid: 25949894", "Include": "true"}, {"number": "37", "ReferenceId": "28734759", "FullCitation": "Overman MJ, et al. Lancet Oncol. (2017) pmid: 28734759", "Include": "true"}, {"number": "38", "ReferenceId": "29355075", "FullCitation": "Overman MJ, et al. J. Clin. Oncol. (2018) pmid: 29355075", "Include": "true"}, {"number": "39", "ReferenceId": "35322232", "FullCitation": "Shitara K, et al. Nature (2022) pmid: 35322232", "Include": "true"}, {"number": "40", "ReferenceId": "23169436", "FullCitation": "Lipson EJ, et al. Clin. Cancer Res. (2013) pmid: 23169436", "Include": "true"}, {"number": "41", "ReferenceId": "26028255", "FullCitation": "Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255", "Include": "true"}, {"number": "42", "ReferenceId": "33001143", "FullCitation": "Oaknin A, et al. JAMA Oncol (2020) pmid: 33001143", "Include": "true"}, {"number": "43", "ReferenceId": "31602320", "FullCitation": "Li G, et al. J Gastrointest Oncol (2019) pmid: 31602320", "Include": "true"}, {"number": "44", "ReferenceId": "32757294", "FullCitation": "Zhang EW, et al. Cancer (2020) pmid: 32757294", "Include": "true"}, {"number": "45", "ReferenceId": "30833418", "FullCitation": "Butler TM, et al. Cold Spring Harb Mol Case Stud (2019) pmid: 30833418", "Include": "true"}, {"number": "46", "ReferenceId": "24553385", "FullCitation": "Bettegowda C, et al. Sci Transl Med (2014) pmid: 24553385", "Include": "true"}, {"number": "47", "ReferenceId": "30400802", "FullCitation": "Lapin M, et al. J Transl Med (2018) pmid: 30400802", "Include": "true"}, {"number": "48", "ReferenceId": "30131550", "FullCitation": "Shulman DS, et al. Br. J. Cancer (2018) pmid: 30131550", "Include": "true"}, {"number": "49", "ReferenceId": "30385733", "FullCitation": "Choudhury AD, et al. JCI Insight (2018) pmid: 30385733", "Include": "true"}, {"number": "50", "ReferenceId": "29298117", "FullCitation": "Stover DG, et al. J. Clin. Oncol. (2018) pmid: 29298117", "Include": "true"}, {"number": "51", "ReferenceId": "30793095", "FullCitation": "Hemming ML, et al. JCO Precis Oncol (2019) pmid: 30793095", "Include": "true"}, {"number": "52", "ReferenceId": "31059681", "FullCitation": "Egyud M, et al. Ann. Thorac. Surg. (2019) pmid: 31059681", "Include": "true"}, {"number": "53", "ReferenceId": "28187169", "FullCitation": "Fan G, et al. PLoS ONE (2017) pmid: 28187169", "Include": "true"}, {"number": "54", "ReferenceId": "30923679", "FullCitation": "Bronkhorst AJ, et al. Biomol Detect Quantif (2019) pmid: 30923679", "Include": "true"}, {"number": "55", "ReferenceId": "30093454", "FullCitation": "Raja R, et al. Clin. Cancer Res. (2018) pmid: 30093454", "Include": "true"}, {"number": "56", "ReferenceId": "30860573", "FullCitation": "Hrebien S, et al. Ann. Oncol. (2019) pmid: 30860573", "Include": "true"}, {"number": "57", "ReferenceId": "28450425", "FullCitation": "Goodall J, et al. Cancer Discov (2017) pmid: 28450425", "Include": "true"}, {"number": "58", "ReferenceId": "29330207", "FullCitation": "Goldberg SB, et al. Clin. Cancer Res. (2018) pmid: 29330207", "Include": "true"}]}, "Signatures": {"Signature": {"ServerTime": "2022_11_22 19:22:59", "OpName": "Douglas A. Mata, MD, MPH | Julia Elvin, M.D., Ph.D., Laboratory Director", "Text": "Douglas A. Mata, MD, MPH | Julia Elvin, M.D., Ph.D., Laboratory Director"}}, "reportProperties": {"reportProperty": [{"identifier": "QualityControlMetrics", "key": "MedianCoverageValue", "value": "N/A"}, {"identifier": "AdditionalFindings", "key": "TumorMutationBurdenScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "MicrosatelliteStatusScore", "value": "0 fraction_unstable_loci"}, {"identifier": "AdditionalFindings", "key": "LossOfHeterozygosityScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "BloodTumorMutationalBurdenScore", "value": "0 Muts/Mb"}, {"identifier": "AdditionalFindings", "key": "TumorFractionScore", "value": "0%"}]}, "comments": {"comment": {"commentedBy": "Douglas A. Mata, MD, MPH", "commentedDts": "2022_11_22T19:21:13.000Z", "text": "No genomic alterations attributable to the patient s cervical cancer were detected, suggesting undetectable circulating tumor DNA. Please consider tumor tissue testing, such as with FoundationOne\u00aeCDx, if clinically indicated."}}, "AAC": {"Amendmends": null}}, "variant_report": {"xmlns": "http://foundationmedicine.com/compbio/variant_report_external", "disease": "CERVIX", "disease_ontology": "Cervix adenocarcinoma", "flowcell_analysis": "2000024777", "gender": "female", "pathology_diagnosis": "Cervical Adenocarcinoma", "pipeline_version": "v3.15.0", "purity_assessment": "15.0", "specimen": "ORD_1504083_01*US1439344.01", "study": "CLINICAL_F1LCDx", "test_request": "ORD_1504083_01", "test_type": "FoundationOneLiquidDx", "tissue_of_origin": "Blood", "xsischemaLocation": "http://foundationmedicine.com/compbio/variant_report_external http://integration.foundationmedicine.com/reporting/variant_report_external_2.2.xsd", "samples": {"sample": {"bait_set": "AB1", "name": "SQ_US1439344.01_1", "nucleic_acid_type": "DNA"}}, "quality_control": {"status": "Pass"}, "short_variants": {"short_variant": [{"allele_fraction": "0.5031", "cds_effect": "8332G>T", "depth": "8294", "equivocal": "false", "functional_effect": "missense", "gene": "APC", "percent_reads": "50.31", "position": "chr5:112179623", "protein_effect": "A2778S", "status": "unknown", "strand": "+", "transcript": "NM_000038", "dna_evidence": {"sample": "SQ_US1439344.01_1"}}, {"allele_fraction": "0.4699", "cds_effect": "1630C>T", "depth": "1081", "equivocal": "false", "functional_effect": "missense", "gene": "NOTCH3", "percent_reads": "46.99", "position": "chr19:15298126", "protein_effect": "R544C", "status": "unknown", "strand": "_", "transcript": "NM_000435", "dna_evidence": {"sample": "SQ_US1439344.01_1"}}, {"allele_fraction": "0.4909", "cds_effect": "2140C>T", "depth": "992", "equivocal": "false", "functional_effect": "missense", "gene": "TNFAIP3", "percent_reads": "49.09", "position": "chr6:138202223", "protein_effect": "P714S", "status": "unknown", "strand": "+", "transcript": "NM_006290", "dna_evidence": {"sample": "SQ_US1439344.01_1"}}, {"allele_fraction": "0.4977", "cds_effect": "1397C>T", "depth": "6944", "equivocal": "false", "functional_effect": "missense", "gene": "ERBB2", "percent_reads": "49.77", "position": "chr17:37872076", "protein_effect": "A466V", "status": "unknown", "strand": "+", "transcript": "NM_004448", "dna_evidence": {"sample": "SQ_US1439344.01_1"}}]}, "copy_number_alterations": null, "rearrangements": null, "biomarkers": {"microsatellite_instability": {"status": "MSS"}, "tumor_mutation_burden": {"score": "0.0", "status": "low", "unit": "mutations_per_megabase"}}, "non_human_content": {"non_human": [{"organism": "HHV_4", "reads_per_million": "37", "status": "unknown", "dna_evidence": {"sample": "SQ_US1439344.01_1"}}, {"organism": "HHV_8", "reads_per_million": "13", "status": "unknown", "dna_evidence": {"sample": "SQ_US1439344.01_1"}}]}}}}}